"Aprotinin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
| Descriptor ID |
D007611
|
| MeSH Number(s) |
D12.776.083
|
| Concept/Terms |
Aprotinin- Aprotinin
- Trypsin Inhibitor, Basic, Pancreatic
- Bovine Kunitz Pancreatic Trypsin Inhibitor
- BPTI, Basic Pancreatic Trypsin Inhibitor
- Kallikrein-Trypsin Inactivator
- Inactivator, Kallikrein-Trypsin
- Kallikrein Trypsin Inactivator
- Kunitz Pancreatic Trypsin Inhibitor
- Trypsin Inhibitor, Kunitz, Pancreatic
- Basic Pancreatic Trypsin Inhibitor
- Bovine Pancreatic Trypsin Inhibitor
Contrykal- Contrykal
- Kontrykal
- Kontrikal
- Contrical
|
Below are MeSH descriptors whose meaning is more general than "Aprotinin".
Below are MeSH descriptors whose meaning is more specific than "Aprotinin".
This graph shows the total number of publications written about "Aprotinin" by people in this website by year, and whether "Aprotinin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aprotinin" by people in Profiles.
-
Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May; 143(5):1069-76.
-
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation. 2011 Sep 13; 124(11 Suppl):S62-9.
-
Efficacy and safety of aprotinin in neonatal congenital heart operations. Ann Thorac Surg. 2011 Sep; 92(3):958-63.
-
Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy. J Cardiovasc Pharmacol. 2011 Apr; 57(4):400-6.
-
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
-
Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
-
Renal dysfunction in cardiac surgery: identifying potential risk factors. Perfusion. 2009 Mar; 24(2):139-42.
-
Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009 Feb; 108(2):399-406.
-
Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct; 52(4):355-62.
-
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension. 2008 Oct; 52(4):715-20.